Proficio Capital Partners LLC Sells 806 Shares of AstraZeneca PLC (NASDAQ:AZN)

Proficio Capital Partners LLC reduced its holdings in shares of AstraZeneca PLC (NASDAQ:AZN) by 7.3% during the 3rd quarter, HoldingsChannel reports. The institutional investor owned 10,208 shares of the company’s stock after selling 806 shares during the quarter. Proficio Capital Partners LLC’s holdings in AstraZeneca were worth $795,000 as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD grew its stake in AstraZeneca by 17.2% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 61,271,974 shares of the company’s stock valued at $4,151,177,000 after purchasing an additional 9,002,450 shares during the last quarter. Capital World Investors boosted its position in AstraZeneca by 0.3% during the first quarter. Capital World Investors now owns 9,365,676 shares of the company’s stock worth $634,525,000 after purchasing an additional 29,497 shares in the last quarter. Envestnet Asset Management Inc. boosted its position in AstraZeneca by 16.7% during the second quarter. Envestnet Asset Management Inc. now owns 3,417,933 shares of the company’s stock worth $266,565,000 after purchasing an additional 488,644 shares in the last quarter. Clearbridge Investments LLC boosted its position in AstraZeneca by 5.8% during the second quarter. Clearbridge Investments LLC now owns 3,403,748 shares of the company’s stock worth $265,458,000 after purchasing an additional 186,010 shares in the last quarter. Finally, Fayez Sarofim & Co raised its holdings in shares of AstraZeneca by 4.7% during the first quarter. Fayez Sarofim & Co now owns 2,990,234 shares of the company’s stock valued at $202,588,000 after acquiring an additional 134,784 shares during the last quarter. 20.35% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages have commented on AZN. Deutsche Bank Aktiengesellschaft raised AstraZeneca from a “sell” rating to a “hold” rating in a report on Wednesday. TD Cowen raised their target price on AstraZeneca from $90.00 to $95.00 and gave the stock a “buy” rating in a research note on Monday, August 12th. Finally, Erste Group Bank raised AstraZeneca from a “hold” rating to a “buy” rating in a research note on Wednesday, September 11th. Two analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $89.75.

AstraZeneca Trading Down 0.3 %

NASDAQ:AZN opened at $64.49 on Friday. The firm has a market cap of $199.96 billion, a PE ratio of 31.15, a price-to-earnings-growth ratio of 1.19 and a beta of 0.47. The stock has a fifty day moving average price of $77.07 and a 200 day moving average price of $78.56. AstraZeneca PLC has a 12-month low of $60.47 and a 12-month high of $87.68. The company has a current ratio of 0.89, a quick ratio of 0.69 and a debt-to-equity ratio of 0.69.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.